Complement pathway in Alzheimer's pathology and retinal neurodegenerative disorders - the road ahead.
作者信息
Mirzaei Mehdi, Deng Liting, Gupta Veer Bala, Graham Stuart, Gupta Vivek
机构信息
Department of Molecular Sciences; Australian Proteome Analysis Facility; Department of Clinical Medicine, Macquarie University, Sydney, NSW, Australia.
Department of Molecular Sciences, Macquarie University, Sydney, NSW, Australia.
出版信息
Neural Regen Res. 2020 Feb;15(2):257-258. doi: 10.4103/1673-5374.265550.
Abstract
摘要
相似文献
1
Complement pathway in Alzheimer's pathology and retinal neurodegenerative disorders - the road ahead.阿尔茨海默病病理学和视网膜神经退行性疾病中的补体途径——未来之路
Neural Regen Res. 2020 Feb;15(2):257-258. doi: 10.4103/1673-5374.265550.
2
Driving Difficulties Among Patients with Alzheimer's Disease and Other Neurodegenerative Disorders.阿尔茨海默病和其他神经退行性疾病患者的驾驶困难。
J Alzheimers Dis. 2019;69(4):1019-1030. doi: 10.3233/JAD-181095.
3
Diagnosing the frontal variant of Alzheimer's disease: a clinician's yellow brick road.诊断阿尔茨海默病的额颞叶变异型：临床医生的“黄砖路”
J Clin Mov Disord. 2017 Mar 2;4:2. doi: 10.1186/s40734-017-0052-4. eCollection 2017.
4
Age-related neurodegenerative disease associated pathways identified in retinal and vitreous proteome from human glaucoma eyes.从人青光眼眼中的视网膜和玻璃体蛋白质组中鉴定出与年龄相关的神经退行性疾病相关途径。
Sci Rep. 2017 Oct 4;7(1):12685. doi: 10.1038/s41598-017-12858-7.
5
Biophysical Aspects of Alzheimer's Disease: Implications for Pharmaceutical Sciences : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla.阿尔茨海默病的生物物理方面：对制药科学的影响：主题：阿尔茨海默病的药物发现、开发和递送 客座编辑：Davide Brambilla。
Pharm Res. 2017 Dec;34(12):2628-2636. doi: 10.1007/s11095-017-2266-4. Epub 2017 Sep 28.
6
Active Immunotherapy for Alzheimer's Disease: The Road Ahead.阿尔茨海默病的主动免疫疗法：未来之路
J Prev Alzheimers Dis. 2015 Jun;2(2):78-79. doi: 10.14283/jpad.2015.59. Epub 2015 Apr 15.
7
Impact of estrogen therapy on Alzheimer's disease: a fork in the road?雌激素疗法对阿尔茨海默病的影响：是歧路抉择吗？
CNS Drugs. 2004;18(7):405-22. doi: 10.2165/00023210-200418070-00001.
8
Translational research on prolyl oligopeptidase inhibitors: the long road ahead.脯肽内切酶抑制剂的转化研究：前路漫漫。
Expert Opin Ther Pat. 2011 Jul;21(7):977-81. doi: 10.1517/13543776.2011.587803.
9
Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders.阿尔茨海默病及相关痴呆症中脑微血管的病理改变。
Acta Neuropathol. 1994;87(5):469-80. doi: 10.1007/BF00294173.
10
Retinal Ganglion Cells and Circadian Rhythms in Alzheimer's Disease, Parkinson's Disease, and Beyond.阿尔茨海默病、帕金森病及其他疾病中的视网膜神经节细胞与昼夜节律
Front Neurol. 2017 May 4;8:162. doi: 10.3389/fneur.2017.00162. eCollection 2017.
引用本文的文献
1
Exploring Molecular and Clinical Dimensions of Glaucoma as a Neurodegenerative Disease.探索青光眼作为一种神经退行性疾病的分子和临床层面。
Int J Mol Sci. 2025 Sep 18;26(18):9109. doi: 10.3390/ijms26189109.
2
Clinical characterization of CCT2 and its role in autophagy regulation during age-related macular degeneration.CCT2的临床特征及其在年龄相关性黄斑变性自噬调节中的作用。
Sci Rep. 2025 May 15;15(1):16849. doi: 10.1038/s41598-025-01907-1.
3
Clusterin mediates hydroquinone-induced cytotoxic responses in HL-60 differentiated cells.簇集素介导对苯二酚诱导的HL-60分化细胞的细胞毒性反应。
Sci Rep. 2024 Dec 5;14(1):30402. doi: 10.1038/s41598-024-82140-0.
4
Targeting shared pathways in tauopathies and age-related macular degeneration: implications for novel therapies.针对tau蛋白病和年龄相关性黄斑变性的共同通路：对新型疗法的启示。
Front Aging Neurosci. 2024 Apr 3;16:1371745. doi: 10.3389/fnagi.2024.1371745. eCollection 2024.
5
Precision Medicine in Glaucoma: Artificial Intelligence, Biomarkers, Genetics and Redox State.精准医学在青光眼领域的应用：人工智能、生物标志物、遗传学与氧化还原状态
Int J Mol Sci. 2023 Feb 1;24(3):2814. doi: 10.3390/ijms24032814.
6
Fingolimod effects on the brain are mediated through biochemical modulation of bioenergetics, autophagy, and neuroinflammatory networks.芬戈莫德对大脑的作用是通过对生物能量学、自噬和神经炎症网络的生化调节来介导的。
Proteomics. 2022 Oct;22(19-20):e2100247. doi: 10.1002/pmic.202100247. Epub 2022 Aug 8.
7
Key Genes and Biochemical Networks in Various Brain Regions Affected in Alzheimer's Disease.阿尔茨海默病相关的不同脑区的关键基因和生化网络。
Cells. 2022 Mar 14;11(6):987. doi: 10.3390/cells11060987.
8
Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer's Disease.阿杜卡努单抗、扎戈替奈单抗和吡格列酮作为阿尔茨海默病靶向治疗策略的比较分析
Aging Dis. 2021 Dec 1;12(8):1964-1976. doi: 10.14336/AD.2021.0719. eCollection 2021 Dec.
9
Amyloid-beta peptide neurotoxicity in human neuronal cells is associated with modulation of insulin-like growth factor transport, lysosomal machinery and extracellular matrix receptor interactions.淀粉样β肽在人神经元细胞中的神经毒性与胰岛素样生长因子转运、溶酶体机制及细胞外基质受体相互作用的调节有关。
Neural Regen Res. 2020 Nov;15(11):2131-2142. doi: 10.4103/1673-5374.282261.
本文引用的文献
1
Complement protein levels in plasma astrocyte-derived exosomes are abnormal in conversion from mild cognitive impairment to Alzheimer's disease dementia.在从轻度认知障碍转变为阿尔茨海默病痴呆的过程中，血浆中星形胶质细胞衍生外泌体中的补体蛋白水平异常。
Alzheimers Dement (Amst). 2019 Jan 9;11:61-66. doi: 10.1016/j.dadm.2018.11.002. eCollection 2019 Dec.
2
Upregulation of Proteolytic Pathways and Altered Protein Biosynthesis Underlie Retinal Pathology in a Mouse Model of Alzheimer's Disease.阿尔茨海默病小鼠模型中蛋白水解途径的上调和蛋白质生物合成的改变导致视网膜病变。
Mol Neurobiol. 2019 Sep;56(9):6017-6034. doi: 10.1007/s12035-019-1479-4. Epub 2019 Feb 1.
3
Complement inhibition as a therapeutic strategy in retinal disorders.补体抑制作为视网膜疾病的一种治疗策略。
Expert Opin Biol Ther. 2019 Apr;19(4):335-342. doi: 10.1080/14712598.2019.1575358. Epub 2019 Feb 11.
4
Complement C3aR Inactivation Attenuates Tau Pathology and Reverses an Immune Network Deregulated in Tauopathy Models and Alzheimer's Disease.补体 C3aR 失活可减轻 Tau 病理学并逆转 Tau 病模型和阿尔茨海默病中失调的免疫网络。
Neuron. 2018 Dec 19;100(6):1337-1353.e5. doi: 10.1016/j.neuron.2018.10.031. Epub 2018 Nov 8.
5
Complement C3-Targeted Gene Therapy Restricts Onset and Progression of Neurodegeneration in Chronic Mouse Glaucoma.补体 C3 靶向基因治疗限制慢性小鼠青光眼的神经退行性变的发作和进展。
Mol Ther. 2018 Oct 3;26(10):2379-2396. doi: 10.1016/j.ymthe.2018.08.017. Epub 2018 Aug 24.
6
Age-related neurodegenerative disease associated pathways identified in retinal and vitreous proteome from human glaucoma eyes.从人青光眼眼中的视网膜和玻璃体蛋白质组中鉴定出与年龄相关的神经退行性疾病相关途径。
Sci Rep. 2017 Oct 4;7(1):12685. doi: 10.1038/s41598-017-12858-7.
7
Complement System Part I - Molecular Mechanisms of Activation and Regulation.补体系统 第一部分——激活与调节的分子机制
Front Immunol. 2015 Jun 2;6:262. doi: 10.3389/fimmu.2015.00262. eCollection 2015.
8
Complement system in pathogenesis of AMD: dual player in degeneration and protection of retinal tissue.补体系统在 AMD 发病机制中的作用：视网膜组织变性和保护的双重作用者。
J Immunol Res. 2014;2014:483960. doi: 10.1155/2014/483960. Epub 2014 Sep 4.
9
A novel role of complement in retinal degeneration.补体在视网膜变性中的新作用。
Invest Ophthalmol Vis Sci. 2012 Nov 19;53(12):7684-92. doi: 10.1167/iovs.12-10069.
10
Implication of complement system and its regulators in Alzheimer's disease.补体系统及其调节蛋白在阿尔茨海默病中的作用。
Curr Neuropharmacol. 2009 Mar;7(1):1-8. doi: 10.2174/157015909787602805.
Zotero 插件